{
    "symbol": "CLSN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-16 15:26:06",
    "content": " The first study is a mouse model evaluating two different doses of a vaccine candidate with a plasmid DNA vector expressing both the alpha, that\u2019s the D614G variant or the European variant in the more advanced Delta variant. These costs were primarily associated with the development of GEN-1 to support the OVATION 2 study as well as development of the plasmid DNA vaccine technology platform, which increased to $1.9 million in the first quarter of this year compared to $1.4 million in the same 3-month period in 2021."
}